Wegovy, Saxenda and Zepbound are approved for weight loss in the following individuals: Adults with an initial BMI of 30, defined as obesity Adults with an initial BMI of 27, defined as overweight, with at least one weight-related comorbid condition Weight-related comorbid conditions include high blood pressure, cardiovascular disease (such as coronary artery disease, heart attack or heart failure), high cholesterol, obstructive sleep apnea, type 2 diabetes, fatty liver, GERD/acid reflux, osteoarthritis, urinary incontinence, etc
For many people, lack of insurance coverage , steep copays, and other factors can make these medications, known as GLP-1 or GIP/GLP-1 receptor agonists , difficult to access
TRINITY may be suitable for adults looking for broader nutritional support while eating less on a GLP-1 medicine, particularly where dietary variety has reduced
If future studies confirm these findings, semaglutide could become a valuable adjunct therapy for managing HS in obese individuals
Alzheimers disease and Parkinsons disease